Oligodendrocyte Pathophysiology and Treatment Strategies in Cerebral Ischemia

CNS Neuroscience and Therapeutics

Volumn 20, Issue 7, 2014, Pages 603-612

  Mifsud, Gabriella ^a   Zammit, Christian ^a   Muscat, Richard ^a   Di Giovanni, Giuseppe ^a,b   Valentino, Mario ^a  

^a UNIVERSITY OF MALTA   (Malta)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Excitotoxicity; Hypoxia ischemia; Oligodendrocyte; Oxidative stress; White matter

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUTAMIC ACID; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; AMINO ACID RECEPTOR BLOCKING AGENT;

CELL DISRUPTION; CLINICAL TRIAL (TOPIC); DISEASE PREDISPOSITION; GLIA; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; STEM CELL; WHITE MATTER; ANIMAL; BRAIN ISCHEMIA; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN ISCHEMIA; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; OLIGODENDROGLIA; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 84902549347     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12263     Document Type: Review

References (146)

1. Albert-Weißenberger C, Sirén AL, Kleinschnitz C. Ischemic stroke and traumatic brain injury: The role of the Kallikrein-Kinin System. Prog Neurobiol 2013;101-102:65-82.
2. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke 1996;27:1641-1647.
3. Tekkök SB, Goldberg MP. AMPA/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci 2001;21:4237-4248.
4. McTigue DM, Tripathi RB. The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 2008;107:1-19.
5. Merrill JE, Scolding NJ. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathol Appl Neurobiol 1999;25:435-458.
6. Matute C, Ransom BR. Roles of white matter in central nervous system pathophysiologies. ASN Neuro 2012;4:89-101.
7. Back SA, Han BH, Luo NL, et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002;22:455-463.
8. Lee BJ, Egi Y, van Leyen K, Lo EH, Arai K. Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res 2010;1307:22-27.
9. Petito CK, Olarte JP, Roberts B, Nowak TS, Pulsinelli WA. Selective glial vulnerability following transient global ischemia in rat brain. J Neuropathol Exp Neurol 1998;57:231-238.
10. Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: The role of iron. Glia 2009;57:467-478.
11. Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia 1996;17:83-93.
12. Winterbourn C. Toxicity of iron and hydrogen peroxide: The Fenton reaction. Toxicol Lett 1995;82-83:969-974.
13. Kress GJ, Dineley KE, Reynolds IJ. The relationship between intracellular free iron and cell injury in cultured neurons, astrocytes, and oligodendrocytes. J Neurosci 2002;22:5848-5855.
14. Oubidar M, Boquillon M, Marie C, Schreiber L, Bralet L. Ischemia-induced brain iron delocalization: Effect of iron chelators. Free Radic Biol Med 1994;16:861-867.
15. Selim MH, Ratan RR. The role of iron neurotoxicity in ischemic stroke. Ageing Res Rev 2004;3:345-353.
16. Thorburne SK, Juurlink BH. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. J Neurochem 1996;67:1014-1022.
17. Juurlink BH, Thorburne SK, Hertz L. Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia 1998;22:371-378.
18. Bradl M, Lassmann H. Oligodendrocytes: Biology and pathology. Acta Neuropathol 2010;119:37-53.
19. Richter-Landsberg C, Vollgraf U. Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells. Exp Cell Res 1998;244:218-229.
20. Bhat NR, Zhang P. Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line. J Neurochem 1999;72:112-119.
21. Laszkiewicz I, Mouzannar R, Wiggins RC, Konat GW. Delayed oligodendrocyte degeneration induced by brief exposure to hydrogen peroxide. J Neurosci Res 1999;55:303-310.
22. Káradóttir R, Attwell D. Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 2007;145:1426-1438.
23. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108.
24. Micu I, Jiang Q, Coderre E, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2005;439:988-992.
25. Butt AM. Neurotransmitter-mediated calcium signalling in oligodendrocyte physiology and pathology. Glia 2006;54:666-675.
26. Casaccia-Bonnefil P, Aibel L, Chao MV. Central glial and neuronal populations display differential sensitivity to ceramide-dependent cell death. J Neurosci Res 1996;43:382-389.
27. Morales A, Lee H, Goni FM, Kolesnic R, Fernandez-Checa JC. Sphingolipids and cell death. Apoptosis 2007;12:923-939.
28. Guenther GG, Peralta ER, Rosales KR, Wong SY, Siskind LJ, Edinger AL. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci USA 2008;105:17402-17407.
29. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res 2003;47:393-399.
30. Carpinteiro A, Dumitru C, Schenck M, Gulbins E. Ceramide-induced cell death in malignant cells. Cancer Lett 2008;264:1-10.
31. Gulbins E, Grassmé H. Ceramide and cell death receptor clustering. Biochim Biophys Acta 2002;1585:139-145.
32. Larocca JN, Farooq M, Norton WT. Induction of oligodendrocyte apoptosis by C2-ceramide. Neurochem Res 1997;22:529-534.
33. Craighead M, Pole J, Waters C. Caspases mediate C2-ceramide-induced apoptosis of the human oligodendroglial cell line, MO3. 13. Neurosci Lett 2000;278:125-128.
34. Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001;21:1302-1312.
35. Folkerth RD, Haynes RL, Borenstein NS, et al. Developmental lag in superoxide dismutases relative to other antioxidant enzymes in premyelinated human telencephalic white matter. J Neuropathol Exp Neurol 2004;63:990-999.
36. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA. Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 2004;24:1531-1540.
37. Baud O, Haynes RF, Wang H, et al. Developmental up-regulation of MnSOD in rat oligodendrocytes confers protection against oxidative injury. Eur J Neurosci 2004;20:29-40.
38. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA. Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur J Neurosci 2004;20:1713-1726.
39. Haynes RL, Folkerth RD, Keefe RJ, Sung I, Swzeda LI, Rosenberg P. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol 2003;62:441-450.
40. Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci USA 2005;102:9936-9941.
41. Rosenberg PA, Dai W, Gan XD, et al. Mature myelin basic protein-expressing oligodendrocytes are insensitive to kainate toxicity. J Neurosci Res 2003;71:237-245.
42. Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 2000;20:9235-9241.
43. Itoh T, Beesley J, Itoh A, et al. AMPA glutamate receptor-mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J Neurochem 2002;81:390-402.
44. Desilva TM, Kinney HC, Borenstein NS, et al. The glutamate transporter EAAT2 is transiently expressed in developing human cerebral white matter. J Comp Neurol 2007;501:879-890.
45. Chiu SY, Kriegler S. Neurotransmitter-mediated signaling between axons and glial cells. Glia 1994;11:191-200.
46. Fields RD, Stevens-Graham B. New insights into neuron-glia communication. Science 2002;298:556-562.
47. Verkhratsky A, Kettenmann H. Calcium signalling in glial cells. Trends Neurosci 1996;19:346-352.
48. Matute C, Domercq M, Sánchez-Gómez MV. Glutamate-mediated glial injury: Mechanisms and clinical importance. Glia 2006;53:212-224.
49. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004;36:257-264.
50. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999;399:7-14.
51. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: Pharmacology, mechanisms, and prevention. J Neurosci 1993;13:1441-1453.
52. Matute C. Glutamate and ATP signalling in white matter pathology. J Anat 2011;219:53-64.
53. Matute C, Torre I, Perez-Cerda F, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007;27:9525-9533.
54. Salter MG, Fern R. NMDA receptors are expressed in oligodendrocytes and mediate injury. Nature 2005;438:1167-1171.
55. Deng W, Wang H, Rosenberg PA, Volpe JJ, Jensen FE. Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci USA 2004;101:7751-7756.
56. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-686.
57. Mcdonald JW, Althomsons SP, Hyrc KL, Choi DW, Goldberg MP. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998;4:291-297.
58. Sánchez-Gómez MV, Matute C. AMPA and kainate receptors each mediate excitotoxicity in oligodendroglial cultures. Neurobiol Dis 1999;6:475-485.
59. Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci 2000;20:1190-1198.
60. Wosik K, Ruffini F, Almazan G. OLivier A, Nalbantoglu J, Antel JP. Resistance of human adult oligodendrocytes to AMPA/kainate receptor-mediated glutamate injury. Brain 2004;127:2636-2648.
61. 2+ Influx through AMPA or kainate receptors alone is sufficient to initiate excitotoxicity in cultured oligodendrocytes. Neurobiol Dis 2002;9:234-243.
62. Sanchez-Gomez MV, Alberdi E, Ibarretxe G, Torre I, Matute C. Caspase- dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci 2003;23:9519-9528.
63. Mato S, Sánchez-Gómez MV, Bernal-Chico A, Matute C. Cytosolic zinc accumulation contributes to excitotoxic oligodendroglial death. Glia 2013;61:750-764.
64. Alberdi E, Sánchez-Gómez MV, Torre I, et al. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J Neurosci 2006;26:3220-3228.
65. Káradóttir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005;438:1162-1166.
66. Burzomato V, Frugier G, Pérez-Otaño I, Kittler JT, Attwell D. The receptor subunits generating NMDA receptor mediated currents in oligodendrocytes. J Physiol 2010;588:3403-3414.
67. Paoletti P, Neyton J. NMDA receptor subunits: Function and pharmacology. Curr Opin Pharmacol 2007;7:39-47.
68. Benarroch EE. Oligodendrocytes: Susceptibility to injury and involvement in neurologic disease. Neurology 2009;72:1779-1785.
69. Bakiri Y, Hamilton NB, Káradóttir R, Attwell D. Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter. Glia 2008;56:233-240.
70. Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A. Mechanisms of oxidative glutamate toxicity: The glutamate/cystine antiporter system xc as a neuroprotective drug target. CNS Neurol Disord Drug Targets 2010;9:373-382.
71. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215:593-602.
72. -: Cystine supplier and beyond. Amino Acids 2012;42:231-246.
73. James G, Butt AM. P2X and P2Y purinoreceptors mediate ATP-evoked calcium signalling in optic nerve glia in situ. Cell Calcium 2001;30:251-259.
74. Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: An overview. Trends Neurosci 2009;32:19-29.
75. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013-1067.
76. Domercq M, Perez-Samartin A, Aparicio D, Alberdi E, Pampliega O, Matute C. P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia 2010;58:730-740.
77. Matute C. P2X7 receptors in oligodendrocytes: A novel target for neuroprotection. Mol Neurobiol 2008;38:123-128.
78. Dale N, Frenguelli BG. Release of adenosine and ATP during ischemia and epilepsy. Curr Pharmacol 2009;7:160-179.
79. Agresti C, Meomartini ME, Amadio S, et al. Metabotropic P2 receptor activation regulates oligodendrocyte progenitor migration and development. Glia 2005;50:132-144.
80. Wang LY, Cai WQ, Chen PH, Deng QY, Zhao CM. Downregulation of P2X7 receptor expression in rat oligodendrocyte precursor cells after hypoxia ischemia. Glia 2009;57:307-319.
81. Suprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 2009;71:333-359.
82. Shereen A, Nemkul N, Yang D, et al. Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia-ischemia-induced thrombotic stroke. J Cereb Blood Flow Metab 2011;31:1155-1169.
83. Mronga T, Stahnke T, Goldbaum O, Richter-Landsberg C. Mitochondrial pathway is involved in hydrogen-peroxide-induced apoptotic cell death of oligodendrocytes. Glia 2004;46:446-455.
84. Ibarretxe G, Sánchez-Gómez MV, Campos-Esparza MR, Alberdi E, Matute C. Differential oxidative stress in oligodendrocytes and neurons after excitotoxic insults and protection by natural polyphenols. Glia 2006;53:201-211.
85. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 2002;192:1-15.
86. Zhang Y, Wang H, Li J, et al. Intracellular zinc release and ERK phosphorylation are required upstream of 12-lipoxygenase activation in peroxynitrite toxicity to mature rat oligodendrocytes. J Biol Chem 2006;281:9460-9470.
87. Rodi D, Couture R, Ongali B, Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des 2005;11:1313-1326.
88. Walker K, Perkins M, Dray A. Kinins and kinin receptors in the nervous system. Neurochem Int 1995;26:1-16.
89. Raidoo DM, Bhoola KD. Kinin receptors on human neurones. J neuroimmunol 1997;77:39-44.
90. Wagner S, Kalb P, Lukosava M, Hilgenfeldt U, Schwaninger M. Activation of the tissue kallikrein-kinin system in stroke. J Neurol Sci 2002;202:75-76.
91. Noda M, Kariura Y, Amano T, et al. Kinin receptors in cultured rat microglia. Neurochem Int 2004;45:437-442.
92. Rosin C, Colombo S, Calver AA, Bates TE, Skaper SD. Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia 2005;52:336-343.
93. Melani A, Cipriani S, Vannucchi MG, et al. Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia. Brain 2009;132:1480-1495.
94. Back SA, Craig A, Ling Luo N, et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol 2006;60:696-705.
95. Noda M, Nakanishi H, Nabekura J, Akaike N. AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia. J Neurosci 2000;20:251-258.
96. Buntinx M, Moreels M, Vandenabeele F, et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-γ and TNF-α on apoptosis. J Neurosci Res 2004;76:834-845.
97. Volpe JJ, Kinney HC, Jensen FE, Rosenberg PA. The developing oligodendrocyte: Key cellular target in brain injury in the premature infant. Int J Dev Neurosci 2011;29:423-440.
98. Takahashi JL, Giuliani F, Power C, Imai Y, Yong VW. Interleukin-1β promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol 2003;53:588-595.
99. Kaur C, Ling EA. Periventricular white matter damage in the hypoxic neonatal brain: Role of microglial cells. Prog Neurobiol 2009;87:264-280.
100. Billiards SS, Haynes RL, Folkerth RD, et al. Development of microglia in the cerebral white matter of the human fetus and infant. J Comp Neurol 2006;497:199-208.
101. Folkerth RD, Keefe RJ, Haynes RL, Trachtenberg FL, Volpe JJ, Kinney HC. Interferon-γ expression in periventricular leukomalacia in the human brain. Brain Pathol 2004;14:265-274.
102. Haynes RL, Folkerth RD, Trachtenberg FL, Volpe JJ, Kinney HC. Nitrosative stress and inducible nitric oxide synthase expression in periventricular leukomalacia. Acta Neuropathol 2009;118:391-399.
103. Sharp J, Keirstead HS. Therapeutic applications of oligodendrocyte precursors derived from human embryonic stem cells. Curr Opin Biotechnol 2007;18:434-440.
104. Mandai K, Matsumoto M, Kitagawa K, et al. Ischemic damage and subsequent proliferation of oligodendrocytes in focal cerebral ischemia. Neuroscience 1997;77:849-861.
105. Gensert JM, Goldman JE. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 1997;19:197-203.
106. Nishiyama A, Chang A, Trapp BD. NG2+ glial cells: A novel glial cell population in the adult brain. J Neuropathol Exp Neurol 1999;58:1113-1124.
107. Di Bello IC, Dawson MR, Levine JM, Reynolds R. Generation of oligodendroglial progenitors in acute inflammatory demyelinating lesions of the rat brain stem is associated with demyelination rather than inflammation. J Neurocytol 1999;28:365-381.
108. Greenwood K, Butt AM. Evidence that perinatal and adult NG2-glia are not conventional oligodendrocyte progenitors and do not depend on axons for their survival. Mol Cell Neurosci 2003;23:544-558.
109. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JPY. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4:1116-1122.
110. Sun J, Fang YQ, Ren H, et al. WIN55, 212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats. Acta Pharmacol Sin 2013;34:119-128.
111. Stevens B, Porta S, Haak LL, Gallo V, Fields RD. Adenosine: A neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 2002;36:855-868.
112. Iwai M, Stetler RA, Xing J, et al. Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic/ischemic brain injury. Stroke 2010;41:1032-1037.
113. Dronne MA, Grenier E, Chapuisat G, Hommel M, Boissel JP. A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients. Prog Biophys Mol Biol 2008;97:60-78.
114. Ginsberg MD. Neuroprotection for ischemic stroke: Past, present and future. Neuropharmacology 2008;55:363-389.
115. Kanellopoulos GK, Xu XM, Hsu CY, Lu X, Sundt TM, Kouchoukos NT. White matter injury in spinal cord ischemia protection by AMPA/kainate glutamate receptor antagonism. Stroke 2000;31:1945-1952.
116. Martinez-Vila E, Sieira PI. Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 2001;11:60-70.
117. Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: A protective role for topiramate. J Neurosci 2004;24:4412-4420.
118. McCracken E, Fowler JH, Dewar D, Morrison S, McCulloch J. Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502. J Cereb Blood Flow Metab 2002;22:1090-1097.
119. Fern R, Möller T. Rapid ischemic cell death in immature oligodendrocytes: A fatal glutamate release feedback loop. J Neurosci 2000;20:34-42.
120. Manning SM, Talos DM, Zhou C, et al. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia. J Neurosci 2008;28:6670-6678.
121. Baltan S. Ischemic injury to white matter: An age-dependent process. Neuroscientist 2009;15:126-133.
122. Zhang M, Li WB, Geng JX, et al. The upregulation of glial glutamate transporter-1 participates in the induction of brain ischemic tolerance in rats. J Cereb Blood Flow Metab 2007;27:1352-1368.
123. Romera C, Hurtado O, Mallolas J, et al. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection. J Cereb Blood Flow Metab 2007;27:1327-1338.
124. Liu HN, Giasson BI, Mushynski WE, Almazan G. AMPA receptor-mediated toxicity in oligodendrocyte progenitors involves free radical generation and activation of JNK, calpain and caspase 3. J Neurochem 2002;82:398-409.
125. Cervetto C, Mazzotta MC, Frattaroli D, et al. Calmidazolium selectively inhibits exocytotic glutamate release evoked by P2X7 receptor activation. Neurochem Int 2012;60:768-772.
126. Irving EA, Yatsushiro K, McCulloch J, Dewar D. Rapid alteration of tau in oligodendrocytes after focal ischemic injury in the rat: Involvement of free radicals. J Cereb Blood Flow Metab 1997;17:612-622.
127. Kubo K, Nakao S, Jomura S, et al. Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. Brain Res 2009 Jul;1279:139-146.
128. Nakase T, Yoshioka S, Suzuki A. Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. BMC Neurol 2011;11:39.
129. Li J, Lin JC, Wang H, et al. Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci 2003;23:5816-5826.
130. Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 2001;32:2149-2154.
131. Porciúncula LO, Rocha JB, Cimarosti H, et al. Neuroprotective effect of ebselen on rat hippocampal slices submitted to oxygen-glucose deprivation: Correlation with immunocontent of inducible nitric oxide synthase. Neurosci Lett 2003;346:101-104.
132. Namura S, Nagata I, Takami S, Masayasu H, Kikuchi H. Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. Stroke 2001;32:1906-1911.
133. Yamaguchi T, Sano K, Takakura K, et al. Ebselen in acute ischemic stroke a placebo-controlled, double-blind clinical trial. Stroke 1998;29:12-17.
134. Vollgraf U, Wegner M, Richter-Landsberg C. Activation of AP-1 and NF-kappaB transcription factors is involved in hydrogen peroxide-induced apoptotic cell death of oligodendrocytes. J Neurochem 1999;73:2501-2509.
135. Rees S, Harding R, Walker D. The biological basis of injury and neuroprotection in the fetal and neonatal brain. Int J Dev Neurosci 2011;29:551-563.
136. Olivier P, Fontaine RH, Loron G, et al. Melatonin promotes oligodendroglial maturation of injured white matter in neonatal rats. PLoS ONE 2009;4:e7128.
137. Villapol S, Fau S, Renolleau S, Biran V, Charriaut-Marlangue C, Baud O. Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr Res 2011;69:51-55.
138. Taylor LC, Puranam K, Gilmore W, Ting JP, Matsushima GK. 17β-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss. Neurobiol Dis 2010;39:127-137.
139. Prokai L, Prokai-Tatrai K, Perjesi P, et al. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA 2003;100:11741-11746.
140. Lin SY, Fan LW, Pang Y, Rhodes PG, Mitchell HJ, Cai ZW. IGF-1 protects oligodendrocyte progenitor cells and improves neurological functions following cerebral hypoxia-ischemia in the neonatal rat. Brain Res 2005;1063:15-26.
141. Cao Y, Gunn AJ, Bennet L, et al. Insulin-like growth factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J Cereb Blood Flow Metab 2003;23:739-747.
142. Mason JL, Ye P, Suzuki K, D'ercole AJ, Matsushima GK. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 2000;20:5703-5708.
143. Linker RA, Maurer M, Gaupp S, et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002;8:620-624.
144. Gerstner B, Lee J, DeSilva TM, Jensen FE, Volpe JJ, Rosenberg PA. 17β-Estradiol protects against hypoxic/ischemic white matter damage in the neonatal rat brain. J Neurosci Res 2009;87:2078-2086.
145. Lechpammer M, Manning SM, Samonte F, et al. Minocycline treatment following hypoxic-ischemic injury attenuates white matter injury in a rodent model of periventricular leukomalacia. Neuropathol Appl Neurobiol 2008;34:379-393.
146. Ness J, Valentino M, McIver SR, Goldberg MP. Identification of oligodendrocytes in experimental disease models. Glia 2005;50:321-328.